gut atrophy), ED supplemented with casein or whey or a soya protein-rich feed. 32
Effects on regional gut growth and intraluminal growth factor activity were then 33 determined. Despite calorie intake being similar in all groups, soya rich feed caused 34 20% extra total body weight gain. Stomach weight was highest on soya and casein 35 diets. Soya enhanced diet caused greatest increase in small intestinal weight and 36 preserved luminal growth factor activity at levels sufficient to increase proliferation in 37 vitro. Regional small intestinal proliferation was highest in proximal segment in ED 38 fed animals whereas distal small intestine proliferation was greater in soya fed 39 animals. Colonic weight and proliferation throughout the colon was higher in animals 40 receiving soya or whey supplemented feeds. We conclude that specific protein 41 supplementation with either soya, casein or whey may be beneficial to rest or increase 42 growth in different regions of the bowel through mechanisms that include 43 differentially affecting luminal growth factor bioactivity. These results have 44 implications for targeting specific regions of the bowel for conditions such as Crohn's 45 disease and chemotherapy. 46 3
INTRODUCTION 48
Many intrinsic inflammatory and ingested injurious agents cause regional damage to 49 the gut. These include Crohn's disease (mainly affecting distal small intestine), 50 ulcerative colitis (affecting colon) and non-steroidal inflammatory drugs (mainly 51 affecting stomach and small intestine). Therapeutic targeting of drugs may occur 52 through site specific release formulations or topical therapy (such as colonic enemas). 53
As an alternative to pharmacological approaches, there is currently interest in using 54 nutritional manipulation to both reduce the risk of relapse and for treatment when an 55 injury is present. For example, elemental diets (ED), consisting of amino acids, 56 mono/disaccharides and short/medium chain fatty acids, are of proven value in the 57 treatment of inflammatory bowel disease, especially in children.
1, 2 The mechanism(s) 58 of action of EDs are unclear but might include reducing systemic antigenic load and 59 "resting" the bowel. More recently, polymeric diets have been shown to be equally 60 efficacious to ED 3 , establishing the principal that selective additions to feeds may 61 enhance efficacy without losing the beneficial effects of ED. Prolonged use of ED 62 causes intestinal atrophy, particularly of the distal bowel, potentially increasing the 63 risk of bacterial translocation and bacteraemia. 4 Dietary formulations which reduce 64 gut luminal antigenic load whilst minimizing the associated gut atrophy could, 65 therefore, have therapeutic advantages. Similarly, because the gut is second only to 66 the bone marrow in cell turnover, damage to the intestine is a common issue in 67 patients undergoing chemotherapy (chemotherapy induced mucositis) and diets which 68 reduce turnover while chemotherapy is administered or enhancing growth after 69 treatment may also be useful.
96

Diets 97
Three of the four test diets comprised standard elemental E028 ('ED', Nutricia 98 Liverpool, UK) or variants of E028 containing whey protein ('ED+W', 12.5g/100g, 99 the two major components of whey being α-lactoglobin and β-lactoglobin.) 6 100 or casein ('ED+C', 10.5g/100g). Both protein supplemented elemental diets where 101 specifically produced for the studies by Nutricia Liverpool. The fourth group 102 consisted of a commercially available soya protein rich diet ('SP', produced by SDS, 103 Essex, UK). All four diets were similar in terms of digestible protein equivalence and 104 amino-acid content but the SP diet had a higher carbohydrate content, lower added fat 105 and contained some crude fibre (5.3%). Details of the various diets are shown in 106
Supplemental Table 1 . 107
108
Protease inhibitory activity of feeds 109
To determine trypsin inhibitory activity within the feeds, a standard BAPNA substrate 110 assay 7 was undertaken with concentrations of trypsin (0 -50 µg) added to generate a 111 standard curve. Additional tubes, each containing 20 µg trypsin had varying 112 concentrations of the feeds added and any effect on reduction of tryptic activity (due 113 to competitive inhibition) determined. In addition, to reproduce the situation found in 114 vivo, where the feeds would be exposed to gastric juice prior to entering the small 115 intestine, additional samples were pre-incubated with pepsin (1mg/ml) for 1 h. at pH 2, 116
37
o C before neutralization and subsequent BAPNA analyses. 117
118
Animal Experiments 119
All experiments were performed in compliance with relevant United Kingdom lawsand guidelines. were coded, weighed and randomized into the four diet groups (n=10 per group) and 135 fed exclusively on these diets for 14 days. Animals remained in their wire bottomed 136 cages in groups of 5 throughout the study. At the end of the 14 day study, rats were given vincristine sulphate by intraperitoneal 143 injection (1mg/kg, Eli Lilly, Basingstoke, UK) and killed 2 h later. Analyses of tissue 144 was performed using the methods published by our group previously. 8 The weight and 145 unstretched length of the various portions of the gastrointestinal tract were measured. 146
To assess the effect of these various diets on luminal growth factor activity, 1 ml of 147 iced, normal saline was then lavaged through the small intestine, collected into 148
Eppendorf tubes, snap frozen using frozen CO 2 (dry ice) and stored at -70 0 C until 149 assay for growth factor activity. 150
The stomach and samples of the small intestine and colon were then fixed in Carnoy's 151 fluid, and stored in 70% (volume/volume) ethanol. For the intestinal tissues, the 152 position of the various samples was defined by expressing its harvest site as a 153 percentage of that organs total length at 1.5, 50 and 90% small intestinal distance and 154 can be considered as equivalent to duodenum, jejunum and ileum respectively. 155
Similarly, 10, 50 and 90% colon can be considered as proximal, mid and distal colon. Analyses of luminal growth factor activity were determined using thymidine 170 incorporation into primary rat hepatocytes as a bioassay and an EGF-standard curve 171 as described previously by us.
9,10 Briefly, to prepare primary rat hepatocytes for the in 172 vitro assay of luminal growth factor activity, male Sprague-Dawley rats were 173 anaesthetized using Hypnorm (Janssen Pharmaceutica-Crown Chemicals Ltd, 174
Lamberhurst, Kent, UK) and hepatocytes isolated by in situ collagenase perfusion. 175
The basic protocol consists of a two-step perfusion of the liver in situ, via the portal 176 vein, first with calcium-free buffer followed by a calcium supplemented buffer 177 containing collagenases. The digested liver was removed, the cells dispersed, filtered, 178 collected by centrifugation and resuspended in a plating medium. For all studies, 179 hepatocytes were grown in Williams E medium without L-glutamine (Gibco BRL, 180
Paisley, UK) containing 5% fetal calf serum. Cell viability, determined by the ability 181 to exclude 0.2% trypan blue, was greater than 80% in all experiments. respectively, Figure 1A) . 234
235
Small intestine (SI) weight. proliferation and intraluminal growth factor assay: 236 Animals fed on the elemental diets all had similar SI weight whereas SP group small 237 intestinal weight was 17% heavier (p<0.01, Figure 1B) . Correspondingly, luminal 238 growth factor activity equivalent to 3.9 +/-0.4 ng of EGF was present in SP group but 239 unrecordable in all other groups. 240
Small intestinal regional proliferation varied dependent on site with the different diets. 241
Proximal small intestinal proliferation was greatest in the ED, with the other three 242 groups being significantly lower (Figure 2A ). In contrast, SP group had the highestproliferation rate in the mid small intestine (significantly greater than ED+W and 244 ED+C, Figure 3B ) and this difference was particularly marked in the distal small 245 intestine with SP having proliferation rate of 150% of the other diets (Fig 2C) . 246
247
Colon weight and proliferation: Compared to ED fed animals, total colonic weight 248 was 15% higher in ED+W animals and 50% higher in SP animals (both p<0.01, 249 Figure 1C ). Regional proliferation data was similar throughout the colon with ED+W 250 and SP animals having 50% (proximal colon), 80% (mid colon) and 120% (distal 251 colon) higher proliferation compared to ED or ED+C groups (p<0.01, Figure 3) . 252
253
DISCUSSION 254
We have shown different dietary protein sources cause differential regional effects on 255 gut growth and proliferation and that diets containing soya protein result in increased 256 small intestinal luminal growth factor activity. 257
258
Care was taken to ensure caloric intake of the groups were comparable to remove a 259 potential confounding factor. We used fourteen days dietary intervention to reflect 260 what would likely be used in a clinical setting in situations such as pre-or post-261 chemotherapy intervention. We used a rat hepatocyte system to assay intraluminal 262 growth factor activity as this is a robust, reproducible method to determine relative 263 bioactivity of EGF-R type ligands in the gut lumen and has the advantage over most 264 cell lines of maintaining viability in the presence of bile and other luminal contents.
9,
265
10 The in vitro trypsin (inhibition) assay is a simple robust system to examine 266 differential effects of food substances and builds on our earlier in vitro work 5 showing 267 that soya-bean trypsin inhibitor causes marked trypsin inhibition, casein causesmoderate trypsin inhibition (probably acting as a competitive substrate), whereas ED 269 or whey have very limited inhibitory activity. 270
271
The trophic effects of the various diets differed dependent on which region of the gut 272 was analyzed. Compared to ED diet, stomach weight was better maintained in ED+C 273 and SP rats. The effect of ED+C may be due to casein being precipitated in stomach 274 acid, delaying gastric emptying, whereas rapid transit into the small intestine is seen 275 in ED or ED+W animals. The most notable finding of the ED diet was the much higher proliferation rate seen in 278 the proximal small intestine compared to the other diets. This is probably as a result of 279 rapid transit into the proximal intestine, where the ED constituents are rapidly 280 adsorbed. This finding could be explained by the luminal workload hypothesis that 281 suggests that regions actively involved in digestion/absorption have increased 282
proliferation. This would also explain the low mitotic level seen in more distal regions 283 of the small bowel as the majority of the feed would have been adsorbed more 284
proximally. 285 286
The most notable effects of ED+W were the increased weight and proliferation of the 287 colon. Several potential mechanisms might have relevance in explaining these 288 findings. Changes in circulating trophic factors such as glucagon-like peptide-2 289 (GLP-2) may have relevance although it is noteworthy that the trophic effect was 290 restricted to the colon and not the small intestine. GLP-2 is produced by the ileum and 291 colon, is trophic to the small intestine and colon and is rapidly degraded by tissue 292 DPP-IV (dipeptidyl peptidase 4). Liu and co-workers showed oral wheysupplementation decreased colonic tissue DPP-IV in rats receiving continuous 294 intravenous GLP-2, possibly increasing local colonic tissue GLP-2 levels.
12 Therefore, 295 even if circulating levels of GLP-2 remain stable, local changes in DPP-IV as a result 296 of dietary manipulation may alter local concentrations. A further mechanism that 297 would explain our results is our finding that whey proteins are poor substrates for 298 luminal proteases when compared against casein or soya. The amount of nutrient 299 reaching the terminal bowel is, therefore, likely to be higher in the ED+W compared 300 to the other groups. Support for this idea comes from recent studies showing whey 301 supplementation increased colonic short chain fatty acids (SCFAs) concentrations, a 302 known substrate for colonocytes. 13 Further studies to determine the importance of 303 colonic bacteria in maintaining the growth of the colon in these animals could include 304 measurement of colonic SCFAs or use of 'germ free' animals. 305
306
The most notable effects of the SP diet in the current studies were the increased total 307 body weight gain, the increased small and large bowel growth and the finding that 308 bioactive growth factor activity was present in small intestinal washings. The 309 additional increase in body weight in the SP-fed group was not due to differences in 310 total calorie intake as these were well matched across the groups although it should be 311 noted that the SP group received a slightly higher percentage of their calories from 312 protein. We have previously suggested that control of intestinal growth might be 313 mediated by changes in intraluminal growth factor concentrations, with the trophic 314 effect dependent on the relative affinity of the luminal proteases for the ingested food 315 and the luminal growth factors.
5 This idea was supported by our findings that 316 pancreatic diversion away from the gut lumen increases luminal growth factor 317 concentrations and caused associated regional hypertrophy. 5 The current studies 318 extend these findings showing that ingestion of soy based proteins (which includes 319 soya bean trypsin inhibitor) are effective competitive substrates for luminal proteases 320 in vivo, allowing luminal growth factors such as EGF to survive better than when 321 animals are fed whey or casein. These findings may have relevance to the trophic 322 effect on the small and large intestine although it must be noted that the SP diet 323 contained some fibre which may have relevance for colonic growth through acting as 324 a fuel source for colonic bacteria, increasing colonic SCFAs levels in a similar way to 325 that discussed for the whey fed animals. Further studies examining ED supplemented 326 with pure soya protein which has had the fibre further reduced, combined with 327 measurement of colonic SCFAs and possibly the use of germ-free animals could help 328 address this question. 329
330
There is currently much interest in the use of dietary proteins for the prevention and 331 treatment of ill health.
14 Our findings that dietary manipulation can cause regional 332 changes in gut growth and also modulates luminal growth factor levels has potential 333 clinical relevance. ED or polymeric diets are of proven benefit for Crohn's disease, a 334 condition that predominantly affects the small intestine. Specific protein 335 supplementation of ED with whey may have advantages in "resting" the small 336 intestine while preserving colonic growth, which among other advantages should 337 reduce the risk of bacterial translocation. Supplementation of ED with soy protein 338 may have the advantage of locally increasing luminal EGF levels, facilitating repair in 339 a similar way to that shown by us in treating ulcerative colitis with topical therapy. 15 
340
Further studies examining the effect of these proteins on intraluminal growth factor 341 concentrations and injury and repair in animal models of inflammatory bowel disease 342 appear warranted but go beyond the scope of this paper. Similarly, chemotherapyinduced injury to the gut is a common side effect of high dose chemotherapy and 344 systemic administration of several different growth factors to promote repair have 345 been tested or are being assessed. 16 Dietary manipulation to reduce gut cellular 346 turnover prior to treatment of non-gut tumours using systemic chemotherapy (to 347 reduce gut side effects) and/or to increase gut proliferation post treatment, therefore, 348 
